A framework for the rigorous assessment of heterogeneous treatment effects from a single randomized controlled trial
American Journal of Epidemiology · 17.03.2026 · 195 (4) · 1098-1107
DOI: 10.1093/aje/kwaf253 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Epidemiology, online erschienen am 20.11.2025. Verfasst von Jane W Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Sciences Unit, Section of Biostatistics, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Models, Statistical. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIDDK NIH HHS, NIH HHS.
Abstract (Originalsprache)
Randomized controlled trials are the gold standard for estimating the average effect of a treatment in a target population, but the same treatment may benefit some patients while having no effect on or even harming others. This phenomenon, termed heterogeneous treatment effects, can be quantified by estimating treatment effects within subgroups of patients, defined by various combinations of baseline covariates. One approach for quantifying heterogeneous treatment effects is to develop “effect models” that directly model complex interactions between baseline covariates and treatment assignment. “Effect scores,” derived from effect models, can then be used to rank patients based on their predicted treatment benefit, enabling targeted treatment regimens. In this article, we provide a rigorous general framework for developing and evaluating effect models to characterize heterogeneous treatment effects from a single randomized control trial. We address challenges in valid model development, such as overfitting, and illustrate our approach in a real-world dataset with time-to-event outcomes subject to right-censoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Quantitative Sciences Unit, Section of Biostatistics, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.
- Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, United States.
- Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
- Geriatric Research and Education Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, United States.
- Department of Biostatistics, Johns Hopkins School of Public Health, Baltimore, MD, United States.
ORCID-Profile: Jane W Liang, Lu Tian
Förderung
- NIA NIH HHS
- NIDDK NIH HHS
- NIH HHS
- NHLBI NIH HHS
- National Institutes of Health
Zitieren
APA
Liang, J. W., Tian, L., Tamura, M. K., Montez-Rath, M., Frangakis, C., & Charu, V. (2026). A framework for the rigorous assessment of heterogeneous treatment effects from a single randomized controlled trial. American Journal of Epidemiology, 195(4), 1098-1107. https://doi.org/10.1093/aje/kwaf253
Vancouver
Liang JW, Tian L, Tamura MK, Montez-Rath M, Frangakis C, Charu V. A framework for the rigorous assessment of heterogeneous treatment effects from a single randomized controlled trial. American Journal of Epidemiology. 2026;195(4):1098-1107. doi:10.1093/aje/kwaf253
BibTeX
@article{Liang2026,
author = {Liang, Jane W and Tian, Lu and Tamura, Manjula Kurella and Montez-Rath, Maria and Frangakis, Constantine and Charu, Vivek},
title = {A framework for the rigorous assessment of heterogeneous treatment effects from a single randomized controlled trial},
journal = {American Journal of Epidemiology},
year = {2026},
volume = {195},
number = {4},
pages = {1098--1107},
doi = {10.1093/aje/kwaf253}
}
EUVIMED